Emergence delirium
Conditions
Interventions
Experimental group (Group E) :In group E, patients were injected with remimazolam 0.2 mg/kg intravenously 5 min before induction
Control group (group N):The same amount of normal saline was infused intravenously in group N
Sponsors
The First Affiliated Hospital of Bengbu Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. American Society of Anesthesiologists (ASA) Class I.~II patients; 2. Patients aged 1~6 years old; 3. Patients undergoing tonsillectomy or adenoidectomy under elective general anesthesia; 4. Patients with Body Mass Index-for-age (BMI-for-age) of 25%~85% age; 5. Informed consent of family members for this study.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of neurological and psychiatric diseases in the past; 2. Patients who have taken psychotropic drugs in the past 3 months; 3. Patients with dysfunction of heart, liver, kidney, lung and other organs; 4. Patients with a history of allergy to the active ingredient of the study drug; 5. Patients with a history of severe congenital diseases, high fever, convulsions, and gastroesophageal reflux.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of epileptiform EEG in sevoflurane-induced period in children;Incidence of delirium during waking years; | — |
Secondary
| Measure | Time frame |
|---|---|
| FLACC Pain Assessment Scale score;Time to first epileptiform EEG;Number of remedial sedations;Extubation time;Occurrence of adverse events; | — |
Countries
China
Contacts
Public ContactNanhai Wang
The First Affiliated Hospital of Bengbu Medical College
Outcome results
None listed